Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have earned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $122.50.

LNTH has been the subject of a number of research analyst reports. JMP Securities reduced their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. Truist Financial restated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday.

Institutional Investors Weigh In On Lantheus

A number of large investors have recently modified their holdings of LNTH. Farallon Capital Management LLC grew its holdings in shares of Lantheus by 595.3% during the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after buying an additional 1,269,900 shares in the last quarter. Swedbank AB purchased a new stake in shares of Lantheus in the first quarter valued at about $26,346,000. Groupama Asset Managment purchased a new stake in shares of Lantheus in the third quarter valued at about $439,000. Vanguard Group Inc. grew its holdings in shares of Lantheus by 5.6% in the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock valued at $458,271,000 after purchasing an additional 389,828 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Lantheus in the second quarter valued at about $26,794,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

LNTH opened at $90.52 on Monday. The firm has a fifty day moving average price of $103.13 and a 200 day moving average price of $96.93. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a market cap of $6.29 billion, a P/E ratio of 15.06 and a beta of 0.51.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.